CLEAR Trial: CA330 Cytokine Adsorption Column for Anticoagulant/Antiplatelet Patients in Non-Elective CPB Surgery.
Key facts
- Who runs it
- Beijing Anzhen Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 120 people, planned
- Started
- 15 Dec 2025
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- CA330 Cytokine Adsorption Column
- Record updated
- 16 December 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients scheduled to undergo non-elective cardiovascular surgery requiring cardiopulmonary bypass
- Patients currently receiving one or more of the following medications - indobufen, ticagrelor, warfarin, cilostazol, dabigatran, rivaroxaban, or apixaban - with the last dose administered within the drug washout period
Who cannot take part
- Patients with a history of chronic liver failure, stage 5 chronic kidney disease (CKD5), or requiring regular dialysis
- Patients with advanced-stage malignancy or scheduled cardiovascular surgery related to tumor management
- Patients with allergic reactions to cytokine adsorption column resin or related components
- Patients with known bleeding risk due to hematologic disorders such as heparin-induced thrombocytopenia, hemophilia, or acute sickle cell crisis
- Patients with severe infection, including severe sepsis
- Patients in special physiological states: pregnancy or puerperium
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate whether the CA330 cytokine adsorption column can reduce perioperative severe bleeding adverse events in patients receiving anticoagulant and/or antiplatelet therapy who undergo non-elective cardiac surgery with cardiopulmonary bypass.
Read full original descriptionShow less
The main questions it aims to answer are:
* Does the use of the CA330 cytokine adsorption column lower the incidence of perioperative severe bleeding compared with standard care? * Does the intervention improve short-term clinical outcomes, such as transfusion requirements, reoperation rates for bleeding, or overall postoperative recovery?
If there is a comparison group: Researchers will compare patients treated with the CA330 cytokine adsorption column versus patients receiving standard cardiopulmonary bypass management to see if cytokine adsorption provides additional safety and efficacy benefits.
Participants will:
* Undergo non-elective cardiac surgery requiring cardiopulmonary bypass. * Be randomly assigned to receive either the CA330 cytokine adsorption column integrated into the CPB circuit (intervention arm) or standard CPB management without the device (control arm). * Be monitored for perioperative bleeding outcomes, transfusion needs, reoperation rates, and overall postoperative prognosis.
The 2 groups in the trial
- CA330 GroupTreatment being tested
CA330 Cytokine Adsorption Column and Standard Cardiopulmonary Bypass Management
Treatment: CA330 Cytokine Adsorption Column
- non-CA330 GroupNo study treatment, for comparison
Standard Cardiopulmonary Bypass Management Alone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter Randomized Controlled Trial of the CA330 Haemoadsorption Device in Patients for Limiting Excess Anticoagulation in Non-elective caRdiac Surgery With Cardiopulmonary Bypass
- Criteria questions
- Built from NCT07284199, who can take part
- Record updated
- 16 December 2025